BRTX Stock — BioRestorative Therapies Inc

BioRestorative Therapies Inc (BRTX)

Updated October 16, 2026.

BRTX is a Stock. Its deepest 1-year drawdown was 91.3%.

BioRestorative Therapies develops therapeutic products using cell and tissue protocols, primarily focused on adult stem cells for treating spine disease and metabolic disorders; its pipeline includes BRTX-100, a cell therapy candidate for disc disorders, and ThermoStem, a therapy targeting obesity, alongside a biocosmeceutical platform and delivery devices. The company does not currently distribute to shareholders. This early-stage biotech company appeals primarily to investors seeking exposure to regenerative medicine and cell therapy development rather than income.

BRTX performance

Returns are updating. BRTX's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 91.3%.

BRTX key facts

Asset type

Stock

Asset class

Equity

Inception date

12/19/1997

Distribution frequency

None

Last close

$1.54 (as of 2026-10-16)

Market cap

$2,126,937

Average volume

20697.0

Beta

0.846

Payout ratio

0.0%

EPS

$-21.40

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BRTX risks and drawbacks

The deepest 1-year drawdown on record here is 91.3%.

Who may consider BRTX — and who may not

It is a weaker fit for investors who need monthly cash flow (BRTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BRTX

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions